Incyte

(NASDAQ) INCY

Current Price$116.61

Market Cap$22.99B

Since IPO (1993)+6,038%

5 Year+47%

1 Year+69%

1 Month+13%

Incyte last closing stock price
Metric	Price	Date
Last close	USD 115.09	2026-07-15

Incyte stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.85%	USD 117.26	2026-07-08
1 month	+12.86%	USD 101.98	2026-06-15
3 month	+20.74%	USD 95.32	2026-04-16
Year to date	+16.52%	USD 98.77	2025-12-31
1 year	+68.63%	USD 68.25	2025-07-15
3 year	+86.35%	USD 61.76	2023-07-14
5 year	+46.93%	USD 78.33	2021-07-16
Since inception	+6,038.13%	USD 1.88	1993-11-04

Incyte Financials at a Glance

Market Cap

$22.99B

Revenue (TTM)

$5.36B

Net Income (TTM)

$1.43B

EPS (TTM)

$7.07

P/E Ratio

16.27

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$116.61

Volume

1,353,630

Open

$115.01

Price

$116.61

Volume

1,353,630

Open

$115.01

Previous Close

$116.65

Daily Range

$114.13 - $117.18

52-Week Range

$67.17 - $118.97

Estimated Earnings Date

Jul 28, 2026

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$116.61

Volume

1,353,630

Open

$115.01

Previous Close

$116.65

Daily Range

$114.13 - $117.18

52-Week Range

$67.17 - $118.97

Estimated Earnings Date

Jul 28, 2026

INCY News

A biotech lab technician using multiple pipettes to load blood samples into test tubes.

Page 1

INCY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Incyte

Incyte makes medicines to help people with rare blood cancers and serious skin disorders. These drugs target specific proteins in the body to stop diseases from growing or spreading. The company also creates creams that help patients regain skin color lost to autoimmune conditions.

The Product Portfolio

Hematology: Medicines for rare blood cancers and immune responses, including JAKAFI for myelofibrosis and bone marrow disorders.
Oncology: Targeted therapies like PEMAZYRE for bile duct cancer and ZYNYZ for rare skin and anal cancers.
Dermatology: Medicated creams like OPZELURA for treating atopic dermatitis, a condition causing red and itchy skin, and vitiligo.
Partnered Programs: Licensed drugs such as OLUMIANT, which partner Eli Lilly uses to treat rheumatoid arthritis and alopecia.

Growth and Expansion

Acquired exclusive global rights to the lymphoma drug tafasitamab in February 2024 after terminating a deal with MorphoSys.
Formed a worldwide agreement with Syndax Pharmaceuticals in September 2021 to develop NIKTIMVO for chronic graft-versus-host disease.
Partnered with Enable Injections in October 2025 to use an on-body delivery system for future blood disorder treatments.
Expanded a long-term collaboration with Eli Lilly in October 2025 to include the treatment of Type 1 diabetes.

What Makes Incyte Different

The company maintains a large in-house research hub in Delaware to handle everything from drug discovery to final testing. This central setup allows scientists to quickly move new compounds into clinical trials to see if they work as intended.

Financial Performance

Revenue reached $1.5 billion in Q4 2025, marking a 27.8% increase from Q4 2024.
Net income grew to $299.3 million in Q4 2025, up 48.7% from the previous year.
Free cash flow hit $521.4 million in Q4 2025, a 43.3% rise year-over-year.
Operating income rose to $383.9 million in Q4 2025, up 29% from Q4 2024.

The Bottom Line

Incyte has transitioned from a research-heavy biotech firm into a global commercial business with multiple approved drugs. Its focus on specialized blood and skin treatments has created a diverse portfolio of cancer and autoimmune therapies.

AI Generated • Apr 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,844

CEO

William J. Meury

Website

www.incyte.com

Headquarters

Wilmington, DE 19803, US

INCY Financials

Key Financial Metrics (TTM)

Gross Margin

92.48%

Operating Margin

27.05%

Net Income Margin

26.71%

Return on Equity

29.31%

Return on Capital

25.64%

Return on Assets

19.51%

Earnings Yield

6.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.99B

Shares Outstanding

199.78M

Volume

1.35M

Avg. Volume

1.73M

Financials (TTM)

Gross Profit

$4.96B

Operating Income

$1.45B

EBITDA

$1.87B

Operating Cash Flow

$1.52B

Capital Expenditure

-$65.90M

Free Cash Flow

$1.45B

Cash & ST Invst.

$4.02B

Total Debt

$33.83M

Incyte Performance Analysis

Incyte annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 3,394,635,000	13.7%
2023	2023-12-31	USD 3,695,649,000	8.9%
2024	2024-12-31	USD 4,241,217,000	14.8%
2025	2025-12-31	USD 5,141,242,000	21.2%

Incyte sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	15.4%
Q3	2025-09-30	12.4%
Q4	2025-12-31	10.3%
Q1	2026-03-31	-15.5%

Incyte annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 1.52	-64.4%
2023	2023-12-31	USD 2.65	73.9%
2024	2024-12-31	USD 0.15	-94.1%
2025	2025-12-31	USD 6.41	4038.7%

Incyte sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	155.0%
Q3	2025-09-30	3.4%
Q4	2025-12-31	-30.8%
Q1	2026-03-31	0.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.27B

+20.9%

Gross Profit

$1.17B

+19.2%

Gross Margin

91.79%

N/A

Market Cap

$22.99B

N/A

Market Cap/Employee

$8.08M

N/A

Employees

2,844

N/A

Net Income

$303.33M

+91.7%

EBITDA

$367.97M

+43.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$4.02B

+66.7%

Total Debt

$33.83M

-21.5%

Accounts Receivable

$1.05B

+27.7%

Inventory

$115.62M

+80.7%

Long Term Debt

$29.41M

-9.9%

Short Term Debt

$4.41M

-57.9%

Return on Assets

19.51%

N/A

Return on Invested Capital

24.79%

N/A

Free Cash Flow

$359.15M

+36.6%

Operating Cash Flow

$369.35M

+38.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DGXQuest Diagnostics Incorporated

DGXQuest Diagnostics Incorporated$209.41+3.79%

UTHRUnited Therapeutics Corporation

UTHRUnited Therapeutics Corporation$529.05-0.52%

WATWaters Corporation

WATWaters Corporation$378.19+0.87%

RPRXRoyalty Pharma plc

RPRXRoyalty Pharma plc$58.53+3.94%

WSTWest Pharmaceutical Services, Inc.

WSTWest Pharmaceutical Services, Inc.$362.37+0.94%

ZBHZimmer Biomet Holdings, Inc.

ZBHZimmer Biomet Holdings, Inc.$93.75+4.00%

GMABGenmab A/S

GMABGenmab A/S$28.98-0.34%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

ONDSOndas

ONDSOndas$6.65-0.06%

SOFISoFi Technologies

SOFISoFi Technologies$17.32-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.74-0.05%

SKHYSK Hynix

SKHYSK Hynix$152.31-0.14%

Questions About INCY

What is the current price of Incyte?

Incyte is trading at $116.65 per share.

What is the 52-week range for Incyte?

Over the past 52 weeks, Incyte has traded between $67.17 and $118.97.

How much debt does Incyte have?

As of the most recent reporting period, Incyte reported total debt of $39.43M.

How much cash does Incyte have on hand?

Incyte reported $3.46B in cash and cash equivalents in its most recent financial results.

What is Incyte’s dividend yield?

Incyte does not currently have a dividend yield.

Incyte

Incyte Financials at a Glance

INCY News

5 Best Biotech Stocks for 2026 and How to Invest

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000

Why Incyte Stock Was Tanking This Week

Incyte Surpasses Q3 Revenue Estimates

3 Stocks the World's Smartest Investors Are Buying Hand Over Fist Right Now

2 Under-the-Radar Biotech Stocks to Buy in 2022

Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start

INCY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Incyte

The Product Portfolio

Growth and Expansion

What Makes Incyte Different

Financial Performance

The Bottom Line

INCY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Incyte Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INCY

What is the current price of Incyte?

What is the 52-week range for Incyte?

How much debt does Incyte have?

How much cash does Incyte have on hand?

What is Incyte’s dividend yield?

Premium Investing Services